人工骨移植替代品（ABGS）用于治疗骨肿瘤的刮脱术变得越来越受欢迎。本回顾性分析的目的是确定ABGS Cerasorb（Curasan-AG，德国Kleinostheim）的β‑磷酸三钙（β-TCP）在手术后的吸收情况、骨愈合和重塑，并评估潜在的并发症。 2018年至2021年，43名患有良性和低度恶性骨肿瘤的患者接受了刮脱术和骨腔重新填充，使用了ABGS Cerasorb，并纳入了最终分析。术后在6周、3个月、6个月和1年进行临床随访检查，包括两平面X射线检查。 在平均随访期14.6个月后，所有患者的刮脱后放射学骨愈合均得到观察。16.3％的患者出现了完全吸收；在其他83.7％的患者中，吸收程度为部分吸收。在四名患者中，其中两名患者股骨远端和两名患者肱骨干部位出现骨折，发生在原始手术后6周内。 总之，β‑磷酸三钙（β-TCP）的Cerasorb似乎是一种可靠的骨移植替代品，具有低并发症率，是自体骨移植或异体骨移植的适当替代选择。然而，它表现出延迟吸收的趋势。 III；回顾性队列研究。 © 作者2023年

Artificial bone graft substitutes (ABGS) for curettage of bone tumors are becoming increasingly popular. The aim of this retrospective analysis was to determine the efficacy of the ABGS Cerasorb (Curasan-AG, Kleinostheim, Germany), a beta-tricalcium phosphate (beta-TCP), concerning resorption profile, bone healing, and remodeling after surgery and to evaluate potential complications.Forty-three patients suffering from benign and low-grade malignant bone tumors were treated with curettage and refilling of the bony cavity using the ABGS Cerasorb between 2018 and 2021 and included in the final analysis. Clinical follow-up exams with X-rays in two planes were performed 6 weeks, 3 months, 6 months, and 1 year after surgery.After a mean follow-up period of 14.6 months, radiological consolidation following curettage was observed in all patients. Total resorption was observed in 16.3% of patients; in the other 83.7%, resorption was partial. In four patients, of whom two had a tumor in the distal femur and two in the humeral diaphysis, fractures occurred within 6 weeks after primary surgery.In conclusion, the beta-TCP Cerasorb seems to be a reliable bone graft substitute with low complication rates and is a suitable alternative to autologous bone grafts or allografts. Nonetheless, it shows a tendency of delayed resorption.III; retrospective cohort study.© The Author(s) 2023.